Felbinac

Identification

Name
Felbinac
Accession Number
DB07477
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
CL 83,544 / LJC 10,141
Categories
UNII
94WNJ5U8L7
CAS number
5728-52-9
Weight
Average: 212.2439
Monoisotopic: 212.083729628
Chemical Formula
C14H12O2
InChI Key
QRZAKQDHEVVFRX-UHFFFAOYSA-N
InChI
InChI=1S/C14H12O2/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9H,10H2,(H,15,16)
IUPAC Name
2-(4-phenylphenyl)acetic acid
SMILES
OC(=O)CC1=CC=C(C=C1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UCathepsin L1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Felbinac is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Felbinac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Felbinac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Felbinac is combined with 5-androstenedione.Experimental, Illicit
AbciximabFelbinac may increase the anticoagulant activities of Abciximab.Approved
AcebutololFelbinac may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Felbinac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Felbinac is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolFelbinac may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Felbinac.Approved, Vet Approved
AclarubicinFelbinac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Felbinac.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Felbinac is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Felbinac is combined with Aldosterone.Experimental, Investigational
AldoxorubicinFelbinac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Felbinac is combined with Alendronic acid.Approved
AliskirenFelbinac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Felbinac is combined with Alminoprofen.Experimental
AlprenololFelbinac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Felbinac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Felbinac is combined with Amcinonide.Approved
AmikacinFelbinac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideFelbinac may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinFelbinac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodFelbinac may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Felbinac.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Felbinac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Felbinac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Felbinac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Felbinac is combined with Anisodamine.Investigational
AnnamycinFelbinac may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Felbinac.Approved, Investigational
Antithrombin III humanFelbinac may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanFelbinac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Felbinac is combined with Apocynin.Investigational
ApramycinFelbinac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Felbinac.Approved, Investigational
ArbekacinFelbinac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinFelbinac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanFelbinac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololFelbinac may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Felbinac is combined with Atamestane.Investigational
AtenololFelbinac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Felbinac.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Felbinac.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Felbinac is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Felbinac.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Felbinac.Investigational
BalsalazideFelbinac may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminFelbinac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Felbinac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololFelbinac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinFelbinac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Felbinac is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Felbinac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Felbinac is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Felbinac.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Felbinac is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Felbinac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Betamethasone.Approved, Vet Approved
BetaxololFelbinac may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Felbinac.Approved, Investigational
BevantololFelbinac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Felbinac is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Felbinac.Approved, Investigational
BisoprololFelbinac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinFelbinac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololFelbinac may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Felbinac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Felbinac is combined with Bucillamine.Investigational
BucindololFelbinac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Felbinac is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Felbinac is combined with Bufexamac.Approved, Experimental
BufuralolFelbinac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Felbinac.Approved
BupranololFelbinac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Felbinac.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Felbinac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Felbinac is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Felbinac is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Felbinac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Felbinac.Approved, Vet Approved, Withdrawn
CarteololFelbinac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolFelbinac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Felbinac.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Felbinac is combined with Celecoxib.Approved, Investigational
CeliprololFelbinac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinFelbinac may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Felbinac.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Felbinac.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Felbinac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Felbinac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Felbinac.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Felbinac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Cilazapril.Approved
CinoxacinFelbinac may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidFelbinac may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Felbinac is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Felbinac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Felbinac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Felbinac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Felbinac is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Felbinac.Vet Approved
CloranololFelbinac may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Felbinac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Felbinac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Felbinac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Felbinac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Felbinac is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Felbinac is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Felbinac.Experimental
CyclosporineFelbinac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateFelbinac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinFelbinac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidFelbinac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanFelbinac may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinFelbinac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Felbinac is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Felbinac is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Delapril.Experimental
DesirudinFelbinac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Felbinac is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Felbinac is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Felbinac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Felbinac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Felbinac is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Felbinac.Approved, Investigational
DextranFelbinac may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Felbinac may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Felbinac may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Felbinac may increase the anticoagulant activities of Dextran 75.Approved
DibekacinFelbinac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Felbinac is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Felbinac.Approved, Vet Approved
DicoumarolFelbinac may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Felbinac is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Felbinac.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Felbinac is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Felbinac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Felbinac.Approved
DihydrostreptomycinFelbinac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Felbinac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Felbinac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Felbinac.Approved
DoxorubicinFelbinac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneFelbinac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Felbinac is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Felbinac is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Felbinac is combined with E-6201.Investigational
Edetic AcidFelbinac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanFelbinac may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Felbinac is combined with Enalaprilat.Approved
EnoxacinFelbinac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinFelbinac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Felbinac.Experimental
EpanololFelbinac may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Felbinac is combined with Epirizole.Approved
EpirubicinFelbinac may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Felbinac.Experimental
EplerenoneFelbinac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Felbinac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Felbinac.Approved
EquileninThe risk or severity of adverse effects can be increased when Felbinac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Felbinac is combined with Equilin.Approved
EsmololFelbinac may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Felbinac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Felbinac is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Felbinac.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Felbinac.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Felbinac is combined with Ethenzamide.Experimental
Ethyl biscoumacetateFelbinac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Felbinac is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Felbinac is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Felbinac is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Felbinac is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Felbinac is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Felbinac.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Felbinac is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Felbinac.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Felbinac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Felbinac is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Feprazone.Experimental
Ferulic acidFelbinac may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Felbinac.Approved, Investigational
FleroxacinFelbinac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Felbinac.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Fludrocortisone.Approved, Investigational
FluindioneFelbinac may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineFelbinac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Felbinac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Felbinac is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Felbinac is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Felbinac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Felbinac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Felbinac.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Felbinac.Approved, Nutraceutical, Vet Approved
FondaparinuxFelbinac may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumFelbinac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Felbinac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Felbinac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Fosinopril.Approved
FramycetinFelbinac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Felbinac.Approved, Vet Approved
GabexateFelbinac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinFelbinac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinFelbinac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Felbinac.Approved, Withdrawn
GemifloxacinFelbinac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinFelbinac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinFelbinac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AFelbinac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Felbinac may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinFelbinac may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Felbinac is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Felbinac is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Felbinac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Felbinac is combined with HE3286.Investigational
HeparinFelbinac may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Felbinac is combined with Higenamine.Investigational
HydralazineFelbinac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Felbinac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Felbinac.Approved, Investigational
Hygromycin BFelbinac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Felbinac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Felbinac.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Felbinac is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Felbinac.Approved, Investigational
IdarubicinFelbinac may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxFelbinac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Felbinac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Felbinac is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Felbinac.Approved
IndenololFelbinac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Felbinac is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Felbinac.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Felbinac is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Felbinac.Approved, Investigational
IsepamicinFelbinac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Felbinac is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Felbinac is combined with Istaroxime.Investigational
KanamycinFelbinac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Felbinac.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Felbinac.Approved
LabetalolFelbinac may decrease the antihypertensive activities of Labetalol.Approved
LandiololFelbinac may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Felbinac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Felbinac.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Felbinac.Approved, Investigational
LepirudinFelbinac may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanFelbinac may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololFelbinac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinFelbinac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Felbinac.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Felbinac is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Felbinac.Approved
LonazolacThe risk or severity of adverse effects can be increased when Felbinac is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Felbinac.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Felbinac.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Felbinac is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Felbinac is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Felbinac.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Felbinac is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Felbinac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Felbinac.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Felbinac.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Felbinac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Felbinac.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Felbinac.Approved
MelagatranFelbinac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Felbinac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Felbinac.Approved, Vet Approved
MepindololFelbinac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineFelbinac may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Felbinac.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Felbinac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Felbinac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Felbinac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololFelbinac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Felbinac.Approved
MetoprololFelbinac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideFelbinac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinFelbinac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Felbinac.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Felbinac.Approved
MizoribineThe risk or severity of adverse effects can be increased when Felbinac is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Felbinac.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Felbinac.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Felbinac.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Nabumetone.Approved
NadololFelbinac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinFelbinac may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatFelbinac may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Felbinac.Approved
Nalidixic AcidFelbinac may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Felbinac.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Felbinac is combined with NCX 1022.Investigational
NeamineFelbinac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololFelbinac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinFelbinac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinFelbinac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Felbinac.Approved, Investigational
NetilmicinFelbinac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Felbinac.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Felbinac.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Felbinac is combined with Nitroaspirin.Investigational
NorfloxacinFelbinac may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Felbinac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Felbinac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Felbinac.Approved
OlsalazineFelbinac may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Felbinac is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Felbinac is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Felbinac is combined with Orgotein.Vet Approved
OtamixabanFelbinac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Felbinac.Approved
Oxolinic acidFelbinac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololFelbinac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Felbinac.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Felbinac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Felbinac is combined with Parecoxib.Approved
ParomomycinFelbinac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Felbinac is combined with Parthenolide.Approved, Investigational
PazufloxacinFelbinac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinFelbinac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololFelbinac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateFelbinac may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateFelbinac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Perindopril.Approved
PhenindioneFelbinac may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonFelbinac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Felbinac.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Felbinac.Approved, Investigational
PindololFelbinac may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidFelbinac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinFelbinac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Felbinac.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Felbinac.Approved, Investigational
Piromidic acidFelbinac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Felbinac.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Felbinac is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Felbinac is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorFelbinac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinFelbinac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinFelbinac may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Felbinac.Approved
PractololFelbinac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Felbinac.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Felbinac is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Felbinac is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Felbinac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Felbinac is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Felbinac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Felbinac is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Felbinac can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Felbinac is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Felbinac is combined with Propacetamol.Approved, Investigational
PropranololFelbinac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Felbinac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Felbinac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Felbinac.Vet Approved
Protein CFelbinac may increase the anticoagulant activities of Protein C.Approved
Protein S humanFelbinac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeFelbinac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinFelbinac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Felbinac.Investigational
PuromycinFelbinac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Felbinac.Approved
RamiprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Felbinac is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Felbinac.Approved, Experimental, Investigational
ReviparinFelbinac may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinFelbinac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Felbinac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Felbinac is combined with Risedronate.Approved, Investigational
RivaroxabanFelbinac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Felbinac is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinFelbinac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinFelbinac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinFelbinac may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Felbinac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Felbinac is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Felbinac.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Felbinac.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Felbinac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Felbinac.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Felbinac.Approved, Investigational
SemapimodThe risk or severity of adverse effects can be increased when Felbinac is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Felbinac.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Felbinac is combined with Serrapeptase.Investigational
SisomicinFelbinac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinFelbinac may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Felbinac.Approved
SotalolFelbinac may decrease the antihypertensive activities of Sotalol.Approved
SP1049CFelbinac may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinFelbinac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinFelbinac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Spirapril.Approved
SpironolactoneFelbinac may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Felbinac.Investigational
StreptomycinFelbinac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinFelbinac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Felbinac.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Felbinac.Approved, Investigational
SulodexideFelbinac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Felbinac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Felbinac.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Felbinac is combined with Suxibuzone.Experimental
TacrolimusFelbinac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Felbinac.Approved
TalinololFelbinac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Felbinac.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Felbinac.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Felbinac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Felbinac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Felbinac is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Felbinac.Approved, Investigational
TemafloxacinFelbinac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Felbinac is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Felbinac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Felbinac.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Felbinac is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Felbinac is combined with Teriflunomide.Approved
TertatololFelbinac may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Felbinac.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Felbinac is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololFelbinac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Felbinac is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Felbinac is combined with Tixocortol.Approved, Withdrawn
TobramycinFelbinac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Felbinac is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Felbinac.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Felbinac.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Felbinac is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Felbinac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Felbinac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Felbinac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneFelbinac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Felbinac is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Felbinac.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Felbinac is combined with Triptolide.Investigational
TrovafloxacinFelbinac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinFelbinac may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Felbinac is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Felbinac.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Felbinac is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinFelbinac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Felbinac.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Felbinac.Approved
WarfarinFelbinac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranFelbinac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Felbinac.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Felbinac.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Felbinac is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Felbinac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Felbinac.Withdrawn
Zoptarelin doxorubicinFelbinac may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinFelbinac may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
3332
PubChem Substance
99443948
ChemSpider
3215
BindingDB
223312
ChEBI
31597
ChEMBL
CHEMBL413965
PharmGKB
PA166049177
HET
BP4
Wikipedia
Felbinac
ATC Codes
M02AA08 — Felbinac
PDB Entries
1mhw

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0372 mg/mLALOGPS
logP3.49ALOGPS
logP3.26ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.71ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity62.5 m3·mol-1ChemAxon
Polarizability23.13 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.947
Caco-2 permeable+0.867
P-glycoprotein substrateNon-substrate0.7845
P-glycoprotein inhibitor INon-inhibitor0.9335
P-glycoprotein inhibitor IINon-inhibitor0.9454
Renal organic cation transporterNon-inhibitor0.9085
CYP450 2C9 substrateNon-substrate0.7588
CYP450 2D6 substrateNon-substrate0.9385
CYP450 3A4 substrateNon-substrate0.7859
CYP450 1A2 substrateNon-inhibitor0.7126
CYP450 2C9 inhibitorNon-inhibitor0.9382
CYP450 2D6 inhibitorNon-inhibitor0.9501
CYP450 2C19 inhibitorNon-inhibitor0.9468
CYP450 3A4 inhibitorNon-inhibitor0.9806
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8959
Ames testNon AMES toxic0.9702
CarcinogenicityNon-carcinogens0.5856
BiodegradationNot ready biodegradable0.5248
Rat acute toxicity2.8081 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9725
hERG inhibition (predictor II)Non-inhibitor0.9402
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Biphenyl / Monocarboxylic acid or derivatives / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Carbonyl group / Aromatic homomonocyclic compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid, biphenyls (CHEBI:31597)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serpin family protein binding
Specific Function
Important for the overall degradation of proteins in lysosomes.
Gene Name
CTSL
Uniprot ID
P07711
Uniprot Name
Cathepsin L1
Molecular Weight
37563.97 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:22 / Updated on March 02, 2018 03:23